Boca Biolistics is pleased to announce that our founders have partnered with the Canadian Private Equity Firm, Clairvest Group Inc. Clairvest has invested $25 million to acquire an equity stake in the company. The Clairvest team will work with Boca Bio CEO Valentin Adia and COO Michael Morris to accelerate growth and expand operations in the coming years. This investment marks an inflection point for Boca Bio as we seek to expand our presence in the biopharmaceutical and life science industries as a clinical research organization (CRO), Biobank, and Reference Testing Laboratory.
Since 2007, Boca Bio has demonstrated a successful track record as a critical partner in the research and development of diagnostic devices and therapeutics. Our biospecimen bank offers samples from over 40 countries on five continents, and our clinical site network spans across 14 countries on five continents. Our expertise in the procurement and distribution of biospecimens has enabled investigators around the world to achieve medical advances that have improved diagnostics and medical care. Clairvest is a targeted venture capital firm focused on working with existing leadership teams at successful companies that are poised for additional growth. Their partnership with Boca marks their second investment in the life sciences.
"Boca Bio plays an important role in advancing the development of novel pharmaceutical drugs and diagnostic devices, and we are delighted to partner with Valentin and Michael," noted Sebastien Dhonte, Managing Director of Clairvest, in the announcement of the partnership.
Boca Bio plans to expand our foundational operations in the fields of clinical research, specimen procurement, biobanking, and distribution, to improve current collaborations and embark on new partnerships with world-class researchers and clinicians. In addition, we intend to seize this opportunity to expand on our oncology capabilities and increase our presence in the pharmaceutical industry.
"We chose to partner with Clairvest because we believe in their partnership-oriented investment style and their ability to help us accelerate our growth over the coming years," says Valentin Adia, CEO of Boca Biolistics. "We are excited to work together and take Boca Bio to the next level."
